Enovis Corporation (NYSE:ENOV) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Enovis Corporation (NYSE:ENOV) have earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $51.1667.

A number of equities research analysts have issued reports on the company. Wells Fargo & Company increased their price target on Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Needham & Company LLC cut their target price on shares of Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. UBS Group decreased their price target on shares of Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enovis in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group decreased their price objective on shares of Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, August 8th.

Insider Buying and Selling at Enovis

In other Enovis news, SVP Bradley J. Tandy bought 3,200 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was purchased at an average price of $31.41 per share, for a total transaction of $100,512.00. Following the completion of the purchase, the senior vice president directly owned 43,515 shares in the company, valued at $1,366,806.15. This trade represents a 7.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Damien Mcdonald purchased 6,457 shares of the company’s stock in a transaction on Thursday, September 11th. The stock was bought at an average price of $30.97 per share, for a total transaction of $199,973.29. Following the completion of the purchase, the chief executive officer directly owned 102,753 shares of the company’s stock, valued at $3,182,260.41. The trade was a 6.71% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 12,157 shares of company stock worth $374,760 over the last ninety days. Corporate insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC increased its position in Enovis by 42.8% during the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after buying an additional 367 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in shares of Enovis in the 2nd quarter valued at $46,000. SJS Investment Consulting Inc. raised its position in Enovis by 30,340.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock valued at $46,000 after purchasing an additional 1,517 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in Enovis by 235.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,703 shares of the company’s stock worth $52,000 after purchasing an additional 1,195 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Price Performance

Enovis stock opened at $29.96 on Friday. The firm has a market cap of $1.71 billion, a PE ratio of -2.10 and a beta of 1.67. Enovis has a 52-week low of $25.47 and a 52-week high of $49.75. The company has a quick ratio of 1.15, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The company’s 50 day moving average is $31.29 and its two-hundred day moving average is $31.33.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. The business had revenue of $383.81 million during the quarter. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. On average, research analysts expect that Enovis will post 2.79 EPS for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.